One Dose Does Not Fit All: Why Metabolic Type Should Guide How Often We Prescribe
A medication prescribed at the right dose but the wrong frequency is not the right medication. This is a principle that pharmacology has understood in theory for decades and that clinical practice has been slow to absorb. The standard instruction — take once daily — reflects the average patient, a statistical construct that describes no one in particular. The actual patient sitting across from the clinician metabolizes drugs quickly, slowly, or somewhere in between, and that difference determines not only how well a treatment works but whether it causes harm.
Most antihypertensive drugs are designed with a twenty-four-hour action profile in mind. The once-daily recommendation assumes that the drug will remain at therapeutically effective concentrations throughout that period, then be cleared and replaced by the next dose. For a patient with ordinary metabolic rate, this assumption is reasonable. For patients at either end of the metabolic spectrum, it is often wrong in ways that are clinically significant and frequently overlooked.
A rapid metabolizer clears drugs faster than the standard model predicts. The drug reaches its peak effect, then falls below therapeutic levels well before the next scheduled dose. The result is a period each day during which blood pressure is inadequately controlled, a gap that standard monitoring may miss entirely if measurements happen to be taken during the drug's effective window. For such a patient, twice-daily dosing of a nominally once-daily drug may be not only appropriate but necessary.
A slow metabolizer presents the opposite problem. The drug accumulates. Each successive dose arrives before the previous one has been adequately cleared, and concentrations build beyond the therapeutic range. The clinical consequence is not usually dramatic toxicity — though that can occur — but rather a steady accumulation of side effects that the patient and clinician may attribute to the drug itself rather than to its dosing frequency. This misattribution leads to unnecessary switches, unnecessary escalations, and unnecessary suffering.
A clinical case illustrates the point with unusual clarity. A hypertensive patient responded to amlodipine but consistently developed leg edema within a week of starting treatment, leading to repeated discontinuation. Switching to L-amlodipine, the drug's pharmacologically active isomer with a somewhat different side effect profile, produced a month of successful control before the edema returned. The solution, when it came, was not another drug substitution. It was a change in frequency: from once daily to once every two days. The edema disappeared and did not return.
What this case demonstrates is that the therapeutic problem was never the drug. It was the accumulation of the drug in a patient whose metabolic rate was slower than the standard dosing interval assumed. The dose was appropriate. The frequency was not. And no amount of switching between antihypertensive classes would have resolved a problem rooted in pharmacokinetics rather than pharmacology.
The practical implications extend well beyond antihypertensives. Any drug with a predictable relationship between plasma concentration and effect — which is to say, most drugs in common use — is subject to the same logic. The clinician who suspects slow metabolism should consider extended intervals before concluding that a drug has failed. The clinician who suspects rapid metabolism should consider increased frequency before concluding that a drug is ineffective at standard doses.
What makes this challenging is that metabolic phenotype is not written on the patient's face. It reveals itself through response — through the pattern of when side effects appear, when efficacy fades, how plasma levels track against expectations. This requires the clinician to think in time, not only in dose: to ask not just how much but how often, and to treat the dosing interval as a variable to be adjusted rather than a fixed property of the drug.
Guidelines specify doses. They specify agents. They rarely specify that the interval between doses may need to be individualized with the same care as the dose itself. That gap between guideline and practice is where patients like the one described above spend months on a carousel of drug switches that never addresses the actual problem.
The right question is not always which drug. Sometimes it is simply when.
You can learn more by reading our e-book or listening to our audiobook
Comments